Technical Analysis for RPRX - Royalty Pharma plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 28.21 | 0.50% | 0.14 |
RPRX closed up 0.5 percent on Wednesday, May 15, 2024, on 73 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 200 DMA Resistance | Bearish | 0.50% | |
| Fell Below 20 DMA | Bearish | 0.50% | |
| Bollinger Band Squeeze | Range Contraction | 0.50% |
| Alert | Time |
|---|---|
| Possible NR7 | about 18 hours ago |
| Possible Inside Day | about 18 hours ago |
| Up 1% | about 20 hours ago |
| 60 Minute Opening Range Breakout | about 20 hours ago |
| Rose Above 10 DMA | about 21 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 33.9171 |
| 52 Week Low | 25.5437 |
| Average Volume | 2,610,235 |
| 200-Day Moving Average | 28.37 |
| 50-Day Moving Average | 29.01 |
| 20-Day Moving Average | 28.12 |
| 10-Day Moving Average | 28.27 |
| Average True Range | 0.58 |
| RSI (14) | 47.09 |
| ADX | 13.33 |
| +DI | 15.50 |
| -DI | 18.85 |
| Chandelier Exit (Long, 3 ATRs) | 27.24 |
| Chandelier Exit (Short, 3 ATRs) | 28.96 |
| Upper Bollinger Bands | 28.61 |
| Lower Bollinger Band | 27.62 |
| Percent B (%b) | 0.6 |
| BandWidth | 3.52 |
| MACD Line | -0.19 |
| MACD Signal Line | -0.25 |
| MACD Histogram | 0.0655 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 28.61 | ||||
| Resistance 3 (R3) | 28.62 | 28.50 | 28.54 | ||
| Resistance 2 (R2) | 28.50 | 28.40 | 28.49 | 28.52 | |
| Resistance 1 (R1) | 28.35 | 28.33 | 28.29 | 28.34 | 28.50 |
| Pivot Point | 28.23 | 28.23 | 28.20 | 28.23 | 28.23 |
| Support 1 (S1) | 28.09 | 28.13 | 28.03 | 28.08 | 27.92 |
| Support 2 (S2) | 27.97 | 28.07 | 27.96 | 27.90 | |
| Support 3 (S3) | 27.82 | 27.97 | 27.88 | ||
| Support 4 (S4) | 27.81 |
